Biomedical Engineering Reference
In-Depth Information
References
1. Nichols S (2004) Particle size distribution parameters using the next generation pharmaceuti-
cal impactor. In: Dalby RN, Byron PR, Peart J, Suman JD, Farr SJ (eds) Respiratory drug
delivery-IX. Davis HealthCare International Publishing, River Grove, IL, pp 485-487
2. Bonam M, Christopher D, Cipolla D, Donovan B, Goodwin D, Holmes S, Lyapustina S,
Mitchell J, Nichols S, Petterson G, Quale C, Rao N, Singh D, Tougas T, Van Oort M, Walther
B, Wyka B (2008) Minimizing variability of cascade impaction measurements in inhalers and
nebulizers. AAPS PharmSciTech 9(2):404-413
3. Christopher D, Curry P, Doub B, Furnkranz K, Lavery M, Lin K, Lyapustina S, Mitchell J,
Rogers B, Strickland H, Tougas T, Tsong Y, Wyka B (2003) Considerations for the develop-
ment and practice of cascade impaction testing including a mass balance failure investigation
tree. J Aerosol Med 16:235-247
4. US Food and Drug Administration (FDA) (1998) CDER. Draft guidance for industry metered
dose inhaler (MDI) and dry powder inhaler (DPI) drug products chemistry, manufacturing, and
controls documentation, Rockville, MD. Accessed 6 Jan 2012 at
http://www.fda.gov/cder/
5. Marple VA, Roberts DL, Romay FJ, Miller NC, Truman KG, Van Oort M, Olsson B, Holroyd
MJ, Mitchell JP, Hochrainer D (2003) Next generation pharmaceutical impactor. Part 1:
design. J Aerosol Med 16(3):283-299
6. Purewal TS (2001) Test methods for inhalers to check performance under normal use and
unintentional use conditions. In: Drug delivery to the lungs-12. The Aerosol Society, London,
pp 92-98
7. Stewart E, Holt J, Fitzgerald C, Bell P, Popow J (2006) Impact of using an automated shake-
fire system on the shot weight and dose content uniformity of an HFA metered dose inhaler. In:
Dalby RN, Byron PR, Peart J, Suman JD, Farr SJ (eds) Respiratory drug delivery-2006. Davis
Healthcare International Publishing, River Grove, IL, pp 581-583
8. Miller NC, Roberts DL, Marple VA (2002) The 'Service Head' approach to automating the
next generation pharmaceutical impactor: proof of concept. In: Dalby RN, Byron PR, Peart J,
Farr SJ (eds) Respiratory drug delivery VIII. Davis Horwood International, Raleigh, NC, pp
521-523
9. Holzner PM, Muller BW (1995) Particle size determination of metered dose inhalers with
inertial separation methods: apparatus A and B (BP), four stage impinger and Andersen Mark
II cascade impactor. Int J Pharm 116(1):11-18
10. Mitchell JP, Nagel MW, Wiersema KJ, Doyle CC (2003) Aerodynamic particle size analysis
of aerosols from pressurized metered dose inhalers: comparison of Andersen 8-stage cascade
impactor, next generation pharmaceutical impactor, and model 3321 Aerodynamic Particle
Sizer aerosol spectrometer. AAPS PharmSciTech 4(4):article 54. Accessed 10 Jan 2012 at:
11. Taki M, Zeng XM, Marriott C, Martin G (2006) Comparison of deposition profiles of drugs
from a combination dry powder inhaler using the Andersen cascade impactor (ACI), multi-
stage liquid impinger (MSLI) and next generation impactor (NGI). In: Dalby RN, Byron PR,
Peart J, Suman JD, Farr SJ (eds) Respiratory drug delivery-2006. Davis Healthcare International
Publishing, River Grove, IL, pp 659-662
12. Jozwiakowski J, Lor X, Paulson S, Schultz D (2006) Comparison of Andersen cascade
impactor and next generation impactor performance of beclomethasone pMDIs with oligolactic
acid. In: Dalby RN, Byron PR, Peart J, Suman JD, Farr SJ (eds) Respiratory drug delivery-2006.
Davis Healthcare International Publishing, River Grove, IL, pp 357-359
13. Mitchell JP, Nagel MW (2004) Particle size analysis of aerosols from medicinal inhalers.
KONA Powder Part 22:32-65
14. Roberts DL, Mitchell JP (2011) Influence of stage efficiency curves on full-resolution impactor
data interpretation. Drug delivery to the lungs-22. The Aerosol Society, Edinburgh, pp 181-
184. Available at:
http://ddl-conference.org.uk/index.php?q=previous_conferences
. Visited 4
Aug 2012
Search WWH ::
Custom Search